SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: GregorioAllegri who wrote (4300)6/7/2016 9:46:31 AM
From: Biomaven1 Recommendation

Recommended By
rkrw

  Read Replies (1) of 4474
 
I would assume the PR in the patient without a detectable mutation had tumors of various lineages - thus the portion of the one they biopsied was not ALK-driven, but other parts or other tumors were.

What commentators don't understand yet is the incidence/prevalence distinction. If you start patients on briga or alectinib they are likely going to survive much longer - perhaps more than three years. So prevalence will likely double from here.

Starting patients on criz is nuts - that just produces mutations and brain mets.

They might have a challenge enrolling their briga vs criz trial once doctors realize how much better alectinib is than criz. But perhaps they can go to poorer countries where these drugs are not normally available.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News